Related Experiment Videos
Recent advances in understanding and managing Paget's disease
Ian R Reid1,2
1Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, 1142, New Zealand.
F1000Research
|September 7, 2019
Summary
A single zoledronate infusion offers long-lasting remission for Paget's disease patients, potentially curing some. This bisphosphonate treatment halts disease progression and improves quality of life.
Area of Science:
- Bone Metabolism and Disease
- Pharmacology
- Rheumatology
Background:
- Paget's disease incidence has significantly decreased.
- Zoledronate, a potent bisphosphonate, shows remarkable efficacy in treating Paget's disease.
Purpose of the Study:
- To evaluate the long-term impact of zoledronate on Paget's disease.
- To assess the potential for cure and cost-effectiveness of zoledronate treatment.
Main Methods:
- Biochemical indices were primary endpoints in Paget's disease trials.
- Clinical outcomes like bone pain and quality of life were assessed.
Main Results:
- A single zoledronate infusion achieves biochemical remission in 90% of patients, often lasting years.
- Treatment halts disease progression, relieves bone pain, improves histology, and heals radiological lesions.
Conclusions:
- Zoledronate offers a potentially curative option for Paget's disease.
- The drug is cost-effective, reducing follow-up needs and likely preventing complications like fractures.